First neuroblastoma patient successfully dosed with innovative CAR therapy utilizing natural killer T cells (CAR-NKT)

24-Sep-2018 - Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an engineered NKT cell therapy has been used in humans. Cell Medica is a clinical-stage biopharmaceutical company that is ...

Cell Medica acquires Delenex Therapeutics

13-Jul-2016 - Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically ...

Cell Medica granted Orphan Drug designation for novel cellular therapy

18-Mar-2015 - Cell Medica announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s cancer immunotherapy treatment, referred to as CMD-003, under development for Epstein-Barr Virus (EBV) positive non-Hodgkin lymphomas. Additionally, the company announced ...

Cell Medica begins commercial production at newly licensed cell therapy manufacturing facility in Germany

20-Feb-2015 - Cell Medica announced the start of commercial cell therapy manufacturing at its facility at the Max-Delbrück-Center of Molecular Medicine in Berlin-Buch (Germany). The first product has been successfully manufactured and delivered for use in the patient.Manufacturing at this site will initially ...

Cell Medica Signs an Exclusive License Agreement and Strengthens Collaboration with the Center for Cell and Gene Therapy, Baylor College of Medicine

Agreement focuses on cellular treatments for EBV associated cancers

11-Jan-2011 - Cell Medica announced an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine, for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV). ...

Cell Medica strengthens team with key appointment to senior management

05-Jan-2010 - Cell Medica has announced that is has appointed four key staff to drive forwards the Company’s activities in the commercialisation of cell therapy treatments. The appointments will enable the Company to achieve scale up of its cell manufacturing operations, increase its clinical development ...

Cell Medica announces treatment of first patient in late stage clinical trial of adoptive cell therapy

12-Sep-2008 - Cell Medica has announced the treatment of the first patient in its CMV~IMPACT clinical study, a late-stage randomised confirmatory trial aimed at demonstrating the clinical effectiveness of immunoprophylactic adoptive cellular therapy (IMPACT) for the treatment of cytomegalovirus (CMV) ...